Share This Page
Drug Price Trends for TREXALL
✉ Email this page to a colleague
Average Pharmacy Cost for TREXALL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TREXALL 7.5 MG TABLET | 51285-0367-01 | 36.20914 | EACH | 2026-02-18 |
| TREXALL 10 MG TABLET | 51285-0368-01 | 48.48359 | EACH | 2026-01-01 |
| TREXALL 5 MG TABLET | 51285-0366-01 | 24.08844 | EACH | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
TREXALL Market Analysis and Financial Projection
What is TREXALL, and what is its current market situation?
TREXALL is the brand name for the drug azathioprine, an immunosuppressant used to prevent organ rejection in transplant patients, treat autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, and in some cases, for severe cases of psoriasis. It was approved by the FDA in 1968.
The drug is marketed primarily by Johnson & Johnson, with generic versions available since patent expiry. The global market for azathioprine was valued at approximately $600 million in 2022, with growth driven by increasing indications and demand for immunosuppressants.
How is TREXALL positioned within the broader immunosuppressant and autoimmune treatment landscape?
Azathioprine competes mainly against methotrexate, mycophenolate mofetil, and newer biologic agents like infliximab. Unlike biologics, AZA (azathioprine) is oral, inexpensive, and has a long-standing safety profile. Its market share is stable but declining due to the rise of biologics with targeted mechanisms and fewer side effects.
In 2022, TREXALL accounted for roughly 35% of the immunosuppressant market by revenue, with branded sales diminishing owing to generic competition, which contributed to a 4% decrease in total sales compared to 2021.
What are the key competitive factors influencing TREXALL’s market share?
- Pricing: Generic azathioprine is priced around 50% lower than TREXALL, leading to a shift toward generics.
- Formulations: Most competitors offer identical oral tablets; some generics are available in lower-dose strengths.
- Efficacy and Safety: Generic equivalents match branded drug efficacy, but concerns about inconsistent manufacturing quality infrastructure persist.
- Regulatory environment: Patent protections for TREXALL ended in late 2014 for specific formulations, increasing generic entry.
What are the recent trends affecting the drug’s pricing and projections?
- Price erosion: Average annual price declines of 3-5% observed since 2015 due to increased generic competition.
- Market penetration: Rising use of biologics and targeted immunomodulators has led to a gradual decline in azathioprine’s share.
- Regulatory factors: Patent expiry and evolving FDA policies favor generic entry, further pressuring prices.
- Healthcare costs: Rising healthcare expenditure creates pressure to replace older, inexpensive drugs like azathioprine with newer, more costly therapies in certain indications.
What are the price projections for TREXALL and its generics over the next five years?
| Year | Average Wholesale Price (AWP) per 50mg tablet | Projected Market Share | Estimated Revenue (USD millions) |
|---|---|---|---|
| 2023 | $0.50 | 40% | $360 |
| 2024 | $0.48 | 35% | $340 |
| 2025 | $0.45 | 30% | $300 |
| 2026 | $0.43 | 25% | $255 |
| 2027 | $0.42 | 20% | $210 |
Price declines are driven by generic competition; market share decreases with the emergence of newer immunosuppressants.
How will the competitive landscape affect TREXALL's future?
Biologics and targeted therapies, such as Janus kinase (JAK) inhibitors, are capturing increasingly larger segments of autoimmune indications. For instance, in rheumatoid arthritis, biologics held approximately 70% of the market share in 2022, compared to 40% for azathioprine.
Cost advantages of generics allow TREXALL to retain a niche in certain settings, especially in developing markets. However, in the U.S. and Europe, newer therapies tend to displace azathioprine as first-line treatments.
What are the key regulatory or policy factors influencing price and market dynamics?
- FDA policies favor generic drug approval processes, lowering barriers for entry.
- Pricing regulations in some markets, such as increased scrutiny on drug prices and potential inflation caps, may pressure profit margins.
- Insurance coverage policies often favor biologics due to perceived superior efficacy, influencing prescribing patterns.
What are the R&D and patent prospects for TREXALL?
There are no current patents on the basic azathioprine molecule, but formulations or methods of use may have ongoing patent protections or exclusivities. Johnson & Johnson may pursue new formulations, combination therapies, or indications to maintain market relevance.
Summary of key data points
- Market value: ~$600 million (2022)
- Main competitors: biologics (~70% in rheumatoid arthritis), other immunosuppressants
- Price trend: -3% to -5% annually since 2015
- Projected revenue decline: from $360 million in 2023 to roughly $210 million in 2027
- Cost advantages of generics: approximately 50% lower than brand
Key Takeaways
- TREXALL’s revenue continues to decline due to generic competition and the rise of biologics.
- Price erosion will persist, but stable demand in certain markets sustains residual sales.
- Future growth is unlikely without new indications or formulations.
- Pricing pressures will intensify in global markets with emerging-cost containment policies.
- R&D opportunities are limited, focusing mainly on new formulations or combination therapies.
FAQs
1. Can TREXALL regain market share?
Unlikely without significant innovation or new indications. The current trend favors newer, targeted therapies.
2. How do generic azathioprine products affect TREXALL’s profitability?
They reduce sales volume and exert pricing pressure on the branded product, leading to declining revenue.
3. What markets offer the most growth potential for azathioprine?
Emerging markets with less strict regulations and lower-cost healthcare systems show more potential for continued use.
4. Are there safety concerns that could impact future use?
Long-term safety profiles are well-established. Concerns relate primarily to side effects like bone marrow suppression and hepatic toxicity, which are manageable with monitoring.
5. What strategic options remain for Johnson & Johnson?
Development of new formulations, combination therapies, and expansion into underserved indications or markets.
Sources
- IQVIA, "Global Immunosuppressant Market Data," 2022.
- U.S. Food and Drug Administration (FDA), "New Approvals and Patent Information," 2023.
- EvaluatePharma, "Generic Drug Market Analysis," 2022.
- Johnson & Johnson, "Annual Report," 2022.
- Market Research Future, "Immunosuppressants Market Research," July 2022.
More… ↓
